Media coverage about CytRx (NASDAQ:CYTR) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CytRx earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 48.7710230864697 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s rankings:
- Arimoclomol Has Potential to Slow ALS Patients’ Functional Decline, Phase 2/3 Trial Shows (alsnewstoday.com)
- BRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners (reuters.com)
- CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates (finance.yahoo.com)
- CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting (finance.yahoo.com)
Separately, ValuEngine lowered shares of CytRx from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3228562/cytrx-cytr-earning-somewhat-positive-media-coverage-accern-reports.html.
CytRx Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.